Navigation Links
CYPHER(R) Sirolimus Drug-Eluting Stent Remains Unsurpassed in Terms of Clinical Safety and Efficacy
Date:9/30/2010

results of SORT-OUT IV, comparing Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent and Abbott's XIENCE V (R) Everolimus-eluting Stent in the primary endpoint of MACE (major acute coronary events) at nine months. These findings were presented the week commencing 20th September 2010 at the TCT Congress, one of the largest cardiovascular industry events held annually in Washington DC. This study adds to the unmatched body of clinical safety and efficacy data on the CYPHER(R) Stent with this comparison to the more recently approved XIENCE V(R) Stent in a contemporary setting.

"The SORT OUT consortium has used CYPHER(R) Stent as the comparator in a number of studies and to date, no newer stent has proven a benefit over CYPHER(R) Stent in terms of clinical safety or efficacy," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global Research and Development, Cordis Corporation. "The clinical safety and efficacy of the CYPHER(R) Stent in this real-world randomized study reinforce the excellent sustained clinical outcomes consistently seen over the last 10 years."

The large randomized trial SORT OUT IV included more than 2,600 patients across a wide range of lesion and patient complexity. The study was designed to test whether the XIENCE V(R) stent is non-inferior to the CYPHER(R) Stent. Both drug-eluting stents performed better than planned for the composite endpoint of MACE (4.9 % for XIENCE V(R) Stent vs. 5.2% for CYPHER(R) Stent); these data support the non-inferiority of the XIENCE V(R) stent over the CYPHER(R) stent (non-inferiority p=0.01) . There was no statistically significant difference in key markers of safety including the incidence of cardiac death (1.9% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent: p=0.31), myocardial infarction, (1.1% for XIENCE V(R) Stent vs. 1.4% for CYPHER(R) Stent: p=0.48), or definite or probable stent thrombosis (0.9% for XIENCE V(R) Stent vs. 0.9% for CYPHER(R) Stent: p=0.83).


'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up
2. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
3. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
4. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
5. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. Pre-clinical Data Show OrbusNeichs Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies
10. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
11. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Former NASA scientist ... last week where he discussed Theradome™, the first portable ... The FOX segment shows firsthand how, via laser technology, ... loss solution that will not require surgery or medication.  ... at the base of the hair follicle, which is ...
(Date:5/4/2015)... MUNDELEIN, Ill. , May 4, 2015 ... , with live video and product demonstrations at the ... Radiology imaging equipment such as Kodak and Fuji Cr,s, ... be auctioned at the first event. Various imaging equipment ... www.RadiologyAuction.com . After years of buying ...
(Date:5/4/2015)... , May 4, 2015  Oncobiologics, Inc., a ... antibody (mAb) biosimilars, has completed the construction of ... headquarters in Cranbury, New Jersey ... facility is designed to utilize multiple technologies ... commercial scale.  Through the use of the latest ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2RadiologyAuction Announces Event Starting On May 5th 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 2Oncobiologics opens commercial launch manufacturing facility in Cranbury, New Jersey 3
... The U.S. Food and Drug Administration today is ... because the highest approved dose--80 milligram (mg)--has been associated ... particularly during the first 12 months of use. ... agency is recommending that simvastatin 80 mg be used ...
... Neurologix, Inc. (OTCBB: NRGX) announced today several new results ... its novel, investigational gene therapy NLX-P101 for the treatment ... presentation of study findings to the National Institutes of ... analysis of new data showed patients treated with NLX-P101 ...
Cached Medicine Technology:FDA Announces New Safety Recommendations for High-Dose Simvastatin 2FDA Announces New Safety Recommendations for High-Dose Simvastatin 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 2Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 3Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 4Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 5Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 6Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 7Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 8Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee 9
(Date:5/4/2015)... 04, 2015 Takeda Pharmaceuticals Corp. has ... settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ) ... risk that a patient will develop bladder cancer. According ... 95% of those eligible for the Actos settlement accept ... cancer cases currently pending in courts around the country, ...
(Date:5/4/2015)... Johnson & Wales University (JWU) held a ... academic center on Wednesday, April 22. , Johnson & Wales ... available by the re-alignment of Interstate-195. JWU’s new academic building, ... Chestnut streets in Providence, is scheduled to be completed in ... land the university purchased in 2012. , “It has long ...
(Date:5/4/2015)... 04, 2015 The American Telemedicine Association ... policy reports which identify gaps in coverage and reimbursement, ... issued the State Telemedicine Gaps Reports last September, many ... laws and regulations impact healthcare delivery in their state,” ... of state actions across the nation, ATA reevaluated the ...
(Date:5/4/2015)... Switzerland (PRWEB) May 04, 2015 ... “ The Importance of Data Integrity in a ... McDowall as guest presenter. This webinar will be ... (15:00 GMT). , Data integrity is a critical ... submitted to regulatory agencies. However, in recent years ...
(Date:5/4/2015)... 04, 2015 EY today announced that ... a finalist for the EY Entrepreneur Of The Year® ... awards program recognizes entrepreneurs who demonstrate excellence and extraordinary ... personal commitment to their businesses and communities. Mr. ... of independent judges. Award winners will be announced ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:METTLER TOLEDO Announces Live Webinar on the Importance of Data Integrity in a GXP Regulated Laboratory 2Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2
... ,Stop wasting tax dollars on investigations, -- ... -- Three-fifths favor stripping stats and awards from ... As this year,s,Major League Baseball season-opener approaches, a ... close eye on steroid use among,professional athletes., ...
... Expects Filing of Restated Audited Financial Statements No Later Than ... April 14, 2008 - ... - Confirms 2008 Revenue Guidance -, WARSAW, Ind., March 27 ... the global,orthopedic device industry and other medical markets, today announced that,the filing of its ...
... GPRO ) announced today that the Company will ... of Molecular Diagnostics Roundtable,Conference" in New York on April ... is scheduled to be webcast live and may be ... Gen-Probe,s website,at http://www.gen-probe.com . The webcast will be ...
... 27 Radian Guaranty Inc., the,primary mortgage insurance ... ),announced today that mortgages originated under "stated income" ... for mortgage insurance. In a,message to clients this ... used to verify assets and income are appropriate,with ...
... Prevents return to work almost as often as physical ... -- Depression stops stroke victims from returning to work almost ... The study of 210 men and women, average age 55, ... of them returned to work within six months -- about ...
... UCLA used a high resolution technique to examine the genome, ... stem cell lines and found that while both lines could ... certain genes that could control such things as individual traits ... genome, which contains all the genes on 46 chromosomes, is ...
Cached Medicine News:Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 2Health News:Americans Guess One-Third of Professional Athletes on Performance Enhancing Drugs 3Health News:Symmetry Medical Delays 10-K Filing to Complete Review 2Health News:Symmetry Medical Delays 10-K Filing to Complete Review 3Health News:Symmetry Medical Delays 10-K Filing to Complete Review 4Health News:Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference 2Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 2Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 3Health News:Radian Guaranty Inc. Eliminates 'Stated Income' and 'Stated Asset' Programs 4Health News:Depression After Stroke Can Be Debilitating 2Health News:UCLA researchers examine human embryonic stem cell genome 2Health News:UCLA researchers examine human embryonic stem cell genome 3
Reliavac® 400cc kits with siliconized PVC drain, Y-connector tube...
Reliavac® 100cc low suction evacuator kits with flat drains and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: